Joseph G. Jurcic, MD

Hematology
Cancer Care, Medical Oncology
More specialties
Accepting New Patients
Virtual Visits/Telehealth
Profile Headshot

Overview

Dr. Joseph Jurcic is a Professor of Medicine at Columbia University Medical Center and the Director of the Hematologic Malignancies Section within the Division of Hematology/Oncology. He specializes in Medical Oncology and focuses on leukemia, myelodysplastic syndromes, and myeloproliferative disorders. Based in New York, NY, Dr. Jurcic is affiliated with NewYork-Presbyterian/Columbia University Irving Medical Center. He received his M.D. from the Perelman School of Medicine at the University of Pennsylvania and completed his training at Barnes-Jewish Hospital and Memorial Sloan Kettering Cancer Center. He is board-certified in both Medical Oncology and Hematology.

Dr. Jurcic's clinical expertise includes the treatment of acute and chronic leukemias, myeloproliferative neoplasms, and myelodysplastic syndromes. His research interests encompass acute myeloid leukemia, radioimmunotherapy with alpha and beta particle-emitting radioisotopes, monoclonal antibody therapy, developing novel small molecule inhibitors, and molecular monitoring of minimal residual disease. Recognized as one of New York Magazine's "Best Doctors" from 2014 to 2024, he has authored or co-authored over 80 articles and book chapters. He has served as the principal investigator on more than 25 clinical trials. Additionally, Dr. Jurcic lectures at national and international conferences and is the Leukemia Section Editor for The Oncologist.

Areas of Expertise / Conditions Treated

  • Acute Leukemia
  • Acute Lymphocytic Leukemia
  • Acute Myeloid Leukemia
  • Aplastic Anemia
  • Chronic Leukemia
  • Chronic Lymphocytic Leukemia
  • Chronic Myelogenous Leukemia
  • CMML (Chronic Myelomonocytic Leukemia)
  • Essential Thrombocythemia
  • Hairy Cell Leukemia
  • Hematologic Malignancy
  • Hemolytic Anemia
  • Immune Thrombocytopenia
  • Large Granular Lymphocytic Leukemia
  • Leukemia
  • Lymphoblastic Leukemia
  • Myelodysplastic Syndrome
  • Myelofibrosis
  • Myeloproliferative Disease
  • Polycythemia Vera
  • Rare Diseases & Myeloproliferative Neoplasm

Academic Appointments

  • Professor of Medicine at CUMC

Administrative Titles

  • Director, Hematologic Malignancies Section

Hospital Affiliations

  • NewYork-Presbyterian / Columbia University Irving Medical Center

Gender

  • Male

Schedule an Appointment

Virtual Visits/Telehealth

Virtual Visits allow you to connect with your provider from the comfort, convenience, and safety of your own home.

Schedule Virtual Visit

Phone Appointments

New and Existing Patients:

Connect Patient Portal

For existing patients, login to make an appointment, view documentation or contact your care provider.

Connect Sign In

Location(s)

161 Fort Washington Avenue
New York, NY 10032

Insurance Accepted

Affinity Health Plan

  • Medicaid Managed Care

AgeWell

  • Medicare Managed Care
  • Special Needs

Amida Care

  • Special Needs

Cigna

  • EPO
  • Great West (National)
  • HMO
  • Medicare Managed Care
  • POS
  • PPO

Emblem/GHI

  • Medicare Managed Care
  • PPO

Emblem/HIP

  • ConnectiCare
  • EPO
  • Essential Plan
  • HMO
  • Medicaid Managed Care
  • Medicare Managed Care
  • POS
  • PPO
  • Select Care (Exchange)
  • Vytra

Empire Blue Cross Blue Shield HealthPlus

  • Child/Family Health Plus
  • Essential Plan

Fidelis Care

  • Child/Family Health Plus
  • Essential Plan
  • Medicaid Managed Care
  • Medicare Managed Care

Healthfirst

  • Child/Family Health Plus
  • Leaf (Exchange)
  • Medicare Managed Care

Local 1199

  • Local 1199

MagnaCare (National)

  • MagnaCare

Medicare

  • Railroad
  • Traditional Medicare

Multiplan

  • Multiplan

MVP Health Care

  • Child/Family Health Plus
  • Essential Plan
  • HMO
  • Medicaid Managed Care

Quality Health Management

  • Quality Health Management

RiverSpring

  • Special Needs

UnitedHealthcare

  • Compass (Exchange)
  • Empire Plan
  • HMO
  • Medicaid (Community Plan)
  • Oxford Freedom
  • Oxford HMO
  • Oxford Liberty
  • POS
  • PPO

WellCare

  • Medicare Managed Care
  • New Jersey Services (Medicaid Managed Care)

World Trade Center Health Plan

  • World Trade Center Health Plan

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Credentials & Experience

Education & Training

  • MD, University of Pennsylvania School of Medicine
  • 1988 University of Pennslyvania School of Medicine
  • Internship: Barnes Jewish Hospital
  • Residency: Barnes Jewish Hospital
  • Fellowship: Memorial Sloan-Kettering Cancer Center

Committees, Societies, Councils

Southwest Oncology Group, Leukemia Committee and Leukemia Committee Working Group

Society of Hematologic Oncology, Education Committee

American Association of Cancer Research

American Society of Clinical Oncology, Scientific Program Committee on Leukemia, Myelodysplasia, and Transplantation

American Society of Hematology

Board Certifications

  • Hematology
  • Medical Oncology

Honors & Awards

  • New York Magazine: Top Doctors Castle Connolly, 2014
  • America's Top Doctors Castle Connolly, 2014, 2013, 2012, 2011, 2010
  • Top Doctors: New York Metro Area Castle Connolly, 2015, 2014, 2013, 2011, 2010, 2009, 2007
  • America's Top Doctors for Cancer Castle Connolly, 2014, 2013, 2012, 2011, 2010, 2009, 2008, 2007
  • Louise and Allston Boyer Young Investigator Award for Distinguished Achievement in Biomedical Research Memorial Sloan-Kettering Cancer Center, 2001
  • Super Doctor SuperDoctors.com

America's Top Doctor
NY Top Doctor

Research

Selected Publications

  • Jurcic JG, Nimer SD, Scheinberg DA, DeBlasio T, Warrell RP Jr, Miller WH Jr. Prognostic significance of minimal residual disease detection and PML/RAR-a isoform type: Long-term follow-up in acute promyelocytic leukemia. Blood 2001; 98:2651-2656.
  • Jurcic JG, Larson SM, Sgouros G, McDevitt MR, Finn RD, Divgi CR, Ballangrud Ã…M, Hamacher KA, Ma D, Humm JL, Brechbiel MW, Molinet R, Scheinberg DA. Targeted alpha particle immunotherapy for myeloid leukemia. Blood 2002; 100:1233-1239.
  • Aliff TB, Maslak PB, Jurcic JG, Heaney ML, Cathcart KN, Sepkowitz KA, Weiss MA. Refractory aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin. Cancer 2003; 97:1025-1032.
  • Feldman E, Kalaycio M, Weiner G, Frankel S, Schulman P, Schwartzberg L, Jurcic J, Velez-Garcia E, Seiter K, Scheinberg DA, Levitt D, Wedel N. Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195. Leukemia 2003; 17:314-318.
  • Burke JM, Caron PC, Papadopoulos EB, Divgi CR, Sgouros G, Panageas K, Finn RD, Larson SM, O'Reilly RJ, Scheinberg DA, Jurcic JG. Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias. Bone Marrow Transplant 2003; 32:549-556.
  • Feldman EJ, Brandwein J, Stone R, Kalaycio M, Moore J, O'Connor J, Wedel N, Roboz GJ, Miller C, Chopra R, Jurcic JG, Brown R, Ehmann WC, Schulman P, Frankel SR, Scheinberg D. Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J Clin Oncol 2005; 23:4110-4116.
  • Lamanna N, Jurcic JG, Noy A, Maslak PM, Gencarelli AN, Panageas KS, Heaney ML, Brentjens RJ, Golde D, Scheinberg DA, Zelenetz AD, Weiss MA. Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high quality responses: Molecular remissions predict for durable complete responses. J Clin Oncol 2009; 27:491-497.
  • Raza A, Jurcic JG, Roboz GJ, Maris M, Stephenson JJ, Wood BL, Feldman EJ, Galili N, Grove LE, Drachman JG, Sievers EL. Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial. Leuk Lymph 2009; 50:1336-1344.
  • Maslak PG, Dao T, Krug LM, Chanel S, Korontsvit T, Zakhaleva V, Zhang R, Wolchok JD, Yuan J, Pinilla-Ibarz J, Berman E, Weiss MA, Jurcic J, Frattini MG, Scheinberg DA. Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T cell responses in patients with complete remission from acute myeloid leukemia. Blood 2010; 116:171-179.
  • Rosenblat TL, McDevitt MR, Mulford DA, Pandit-Taskar N, Divgi CR, Panageas K, Weiss MA, Chanel S, Morgenstern A, Sgouros G, Larson SM, Scheinberg DA, Jurcic JG. Sequential cytarabine alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia. Clin Cancer Res 2010; 16:5303-5311.
  • Park JH, Qiao B, Panageas KS, Schymura MJ, Jurcic JG, Rosenblat TL, Altman JK, Douer D, Rowe JM, Tallman MS. Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood 2011; 118:1248-1254.
  • Brentjens R, Riviere I, Park JH, Davila ML, Want X, Stefanski J, Taylor C, Yeh R, Bartido S, Borquez-Ojeda O, Olszewska M, Bernal Y, Pegram H, Przybylowski M, Hollyman D, Usachenko Y, Pirraglia D, Hosey J, Santos E, Halton E, Maslak P, Scheinberg D, Jurcic J, Heaney M, Heller G, Frattini M, Sadelain M. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B cell leukemias. Blood 2011; 118:4817-4828.
  • Sekeres MA, Lancet JE, Wood BL, Grove LE, Sandalic L, Sievers LE, Jurcic JG. Randomized, phase 2b study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated AML. Haematologica 2013 98:119-128.
  • Goldberg JD, Linker A, Kuk D, Ratan R, Jurcic J, Barker JN, Castro-Malaspina HR, Giralt S, Hsu K, Jakubowski AA, Jenq R, Koehne G, Papadopoulos EB, van den Brink MRM, Young JW, Boulad F, Kernan NA, O'Reilly RJ, Yahalom J, Heller G, Perales M-A. T-cell depleted stem-cell transplantation for adults with high-risk acute lymphocytic leukemia in 1st complete remission: long-term survival with a decreased risk of graft-versus-host disease. Biol Blood Marrow Transplant 2013; 19:208-213.
  • Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, Bartido S, Stefanski J, Taylor C, Olszewska M, Borquez-Ojeda O, Qu J, Wasielewska T, He Q, Bernal Y, Rijo IV, Hedvat C, Kobos R, Curran K, Steinherz P, Jurcic J, Rosenblat T, Maslak P, Frattini M, Sadelain M. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 20 March 2013; 5(177):177ra38.
  • Altman JK, Rademaker A, Cull E, Weitner BB, Ofran Y, Rosenblat TL, Haidau A, Park JH, Ram S, Orsini J, Sandhu S, Catchatourian R, Trifilio SM, Adel NG, Frankfurt O, Stein EM, Mallios G, DeBlasio T, Jurcic JG, Nimer S, Peterson LC, Kwaan H, Rowe JM, Douer D, Tallman MS. Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death. Leuk Res 2013; 37:1004-1009.Jurcic JG, Rosenblat TL. Targeted alpha-particle immunotherapy for acute myeloid leukemia. Am Soc Clin Oncol Educ Book. 2014:e126-31.